Esperion (ESPR)
NASDAQ:ESPR
Want to see ESPR full AI Analyst Report?
ESPR Stock Chart & Stats
$2.04
-$0.02(-0.92%)
At close: 4:00 PM EST
$2.04
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $4.18
Previous CloseN/A
Volume1.55M
Average Volume (3M)6.48M
Market Cap
$800.53M
Enterprise Value$777.25M
Total Cash (Recent Filing)$167.85M
Total Debt (Recent Filing)$548.00M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 07, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding257,404,880
10 Day Avg. Volume8,726,188
30 Day Avg. Volume6,483,744
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)-2.55
Price to Sales (P/S)1.91
P/FCF Ratio-59.60
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit2.99
Enterprise Value/Ebitda12.38
Forecast
1Y Price Target
$3.22Price Target Upside57.84% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$400.43M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In High-risk PopulationsClinical evidence indicates bempedoic acid provides consistent benefit in specific high‑risk and statin‑intolerant patient groups, including a reduction in ischemic stroke risk, supporting targeted use where residual cardiovascular risk remains high.
Commercial Expansion And Pipeline DiversificationBroadened commercial efforts, international market entry plans, and acquisitions such as Corstasis aim to diversify the product portfolio and support deeper market penetration for Nexletol and Nexlizet.
Guideline EndorsementsUpdated national dyslipidemia guidelines granted bempedoic acid multiple strong recommendations and Class 1 distinctions, strengthening its role as a non‑statin option for patients unable to tolerate statins.
Bears Say
Direct Competitor With Superior EfficacyA competing oral cholesterol therapy from a major drugmaker demonstrated greater LDL lowering and fewer serious side effects in late‑stage data, creating a direct efficacy and tolerability challenge to bempedoic acid's market position.
Payer And Market Access ConstraintsPayers and large pharmaceutical partners possess scale and contracting leverage that could limit reimbursement and restrict uptake of branded bempedoic acid treatments, especially where out‑of‑pocket costs are a concern.
Shift In Prescriber PreferencesA trend toward prescribing therapies that produce larger cholesterol reductions and clearer links to clinical outcomes raises the risk that clinicians favor alternative agents over bempedoic acid, reducing long‑term commercial durability.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $4.17 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $800.53M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is May 07, 2026 which is in 3 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Mar 10, 2026. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.243 by -$0.023.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.04.
How many shares outstanding does Esperion have?
Esperion has 257,404,880 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of $0.22 in its last earnings report, missing expectations of $0.243. Following the earnings report the stock price went down -11.184%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.22 (57.84% Upside)
$3.22 (57.84% Upside)
Blogger Sentiment
Neutral
ESPR Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 968.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
114.73%
12-Months-Change
Fundamentals
Return on Equity
5.62%
Trailing 12-Months
Asset Growth
16.52%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights: record revenue growth (Q4 +144%), meaningful U.S. product momentum (U.S. sales +38%; Rx equivalents +34%; prescribers +~25%), expanding international adoption (Daiichi +51% royalties; >700,000 patients treated), a stronger balance sheet ($167.9M cash and $55M debt paid), and a strategic acquisition (Corstasis/Enbumyst) that broadens market opportunity. Lowlights were largely transitional or one-time in nature: a large nonrecurring collaboration payment in 2025 that reduces revenue comparability in 2026, rising SG&A/legal costs tied to litigation, modestly higher R&D and operating expense guidance to fund integration and launches, and near-term uncertainty from guideline timing and competitive entrants. Overall, the positives — robust growth, global rollout, pipeline advancement, and a transformative acquisition — outweigh the manageable near-term challenges and one-time items.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$3.22
▲(57.84% Upside)
Technical Analysis
Ownership Overview
1.70% Insiders
12.52% Mutual Funds
8.14% Other Institutional Investors
66.13% Public Companies and
Individual Investors